RecruitingNCT04375033
Comparing daily and long-acting buprenorphine for opioid use disorder
About this title
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
Read the official source — NCT04375033Medication studyAges 18+United StatesAddiction
Understand this study
Who could participate?
Listed age limits: from 18 years.
What will I do during this study?
You are assigned to monthly long-acting injectable buprenorphine or daily buprenorphine tablets taken under the tongue. The registry compares how well the two approaches support treatment retention and continued opioid abstinence.
- Listed locations
- Tuscaloosa and 24 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 3, 2020
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 952
- Sponsor
- VA Office of Research and Development
- Sponsor type
- Government agency
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT04375033
- Official title
Show the full official title
CSP #2014 - Comparative Effectiveness of Two Formulations of Buprenorphine for Treating Opioid Use Disorder in Veterans (VA-BRAVE)
Recruitment & locations
RecruitingTuscaloosa · Phoenix · Long Beach
21 more locations
- Palo Alto
- San Francisco
- West Haven
- Wilmington
- Bay Pines
- Gainesville
- Boston
- Minneapolis
- Cleveland
- Dayton
- Philadelphia
- Pittsburgh
- Providence
- Dallas
- Salt Lake City
- White River Junction
- Hampton
- Salem
- Seattle
- Huntington
- Milwaukee
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is VA Office of Research and Development, a government agency.
Does this study involve medication?
Yes. The study involves medication, including Sublingual buprenorphine with naloxone and Injectable subcutaneous buprenorphine.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as recruiting.
